As a group, analysts forecast that Editas Medicine, Inc. will post -3.04 EPS for the current year.

Source: https://www.americanbankingnews.com/2023/05/27/20801-shares-in-editas-medicine-inc-nasdaqedit-acquired-by-axq-capital-lp.html

Despite the positive news from the BRILLIANCE study, Editas' lack of approved products in its commercial portfolio and its heavy reliance on partnerships could hinder the company's ability to generate regular income.

Source: https://seekingalpha.com/article/4581505-editas-the-potential-of-gene-editing-technology-and-the-risks-of-a-lackluster-pipeline?source=feed_all_articles

Finally, began coverage on Editas Medicine in a research report on Thursday.

Source: https://www.etfdailynews.com/2023/08/17/amalgamated-bank-sells-1687-shares-of-editas-medicine-inc-nasdaqedit/

Finally, MetLife Investment Management LLC boosted its position in Editas Medicine by 57.4% during the 1st quarter.

Source: https://www.americanbankingnews.com/2023/09/03/citigroup-inc-buys-286589-shares-of-editas-medicine-inc-nasdaqedit.html

Quantbot Technologies LP bought a new stake in Editas Medicine during the 1st quarter worth about $44,000.

Source: https://www.etfdailynews.com/2023/05/23/citigroup-inc-has-3-07-million-holdings-in-editas-medicine-inc-nasdaqedit/